

**SUPPLEMENTARY TABLE 1. Estimated vaccination coverage by age 24 months\* among children born during 2020-2021,<sup>†</sup> by selected vaccines and doses and health insurance status<sup>§</sup> -- National Immunization Survey-Child, United States, 2021-2023**

Vaccine/Dose	Health insurance status, % (95% CI)			
	Private Only (referent) (n = 16,007)	Any Medicaid (n = 10,018)	Other insurance (n = 2,074)	Uninsured (n = 569)
<b>DTaP<sup>¶</sup></b>				
≥3 doses	95.6 (94.9–96.2)	90.7 (89.5–91.8)**	90.7 (88.0–93.0)**	79.0 (71.0–86.1)**
≥4 doses	86.3 (84.8–87.7)	74.9 (73.1–76.7)**	74.4 (70.7–78.0)**	59.3 (50.8–68.1)**
<b>Poliovirus (≥3 doses)</b>	95.0 (94.3–95.7)	90.0 (88.8–91.2)**	90.0 (87.3–92.4)**	79.3 (71.2–86.3)**
<b>MMR (≥1 dose)<sup>††</sup></b>	92.9 (91.9–93.8)	88.9 (87.6–90.1)**	87.4 (84.5–90.0)**	81.2 (74.7–86.8)**
<b>Hib<sup>§§</sup></b>				
Primary series	94.7 (93.7–95.5)	89.9 (88.7–91.0)**	89.6 (86.8–92.0)**	76.8 (68.7–84.0)**
Full series	81.8 (80.2–83.3)	73.6 (71.8–75.2)**	75.3 (71.8–78.6)**	58.7 (50.2–67.4)**
<b>HepB</b>				
Birth dose <sup>¶¶</sup>	82.9 (81.5–84.1)	78.4 (76.7–80.0)**	70.6 (66.5–74.3)**	66.6 (58.0–74.3)**
≥3 doses	93.3 (92.5–94.0)	90.1 (88.9–91.3)**	89.3 (86.6–91.7)**	76.0 (68.0–83.3)**
<b>VAR (≥1 dose)<sup>††</sup></b>	92.5 (91.6–93.4)	88.9 (87.6–90.1)**	85.3 (82.2–88.1)**	75.9 (69.0–82.3)**
<b>PCV</b>				
≥3 doses	94.9 (94.1–95.7)	89.7 (88.5–90.8)**	89.7 (86.9–92.1)**	77.7 (70.8–83.9)**
≥4 doses	87.8 (86.3–89.2)	75.9 (74.2–77.6)**	78.1 (74.7–81.4)**	58.0 (49.8–66.4)**
<b>HepA<sup>***</sup></b>				
≥1 dose	89.3 (87.9–90.6)	85.0 (83.5–86.4)**	83.7 (80.3–86.7)**	74.8 (67.6–81.5)**
≥2 doses (by 24 months)	49.8 (48.1–51.5)	44.1 (42.2–46.1)**	43.7 (39.6–47.9)**	23.5 (17.9–30.6)**
≥2 doses (by 35 months)	83.6 (81.7–85.4)	74.2 (71.6–76.6)**	73.0 (67.4–78.3)**	— <sup>†††</sup>
<b>Rotavirus (by 8 months)<sup>§§§</sup></b>	83.7 (82.3–85.1)	69.6 (67.8–71.4)**	69.5 (65.3–73.3)**	48.6 (40.1–57.1)**
<b>Influenza (≥2 doses)<sup>¶¶¶</sup></b>	70.2 (68.5–71.9)	43.7 (41.8–45.7)**	55.4 (51.4–59.5)**	34.5 (27.2–43.2)**
<b>Combined 7-vaccine series<sup>****</sup></b>	74.2 (72.6–75.9)	62.1 (60.1–64.0)**	63.6 (59.7–67.6)**	44.6 (36.6–53.5)**
<b>No vaccinations</b>	0.7 (0.6–0.9)	1.3 (1.0–1.7)**	1.8 (1.2–2.8)**	4.0 (2.6–5.9)**

**Abbreviations:** DTaP = diphtheria and tetanus toxoids and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = *Haemophilus influenzae* type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine; VAR = varicella vaccine.

\* Includes vaccinations received by age 24 months (before the day the child turns 24 months), except for the HepB birth dose (at birth through 3 days), rotavirus vaccination (by 8 months), and ≥2 HepA doses (by 35 months). For all vaccines except the HepB birth dose and rotavirus vaccination, the Kaplan-Meier method was used to estimate vaccination coverage to account for children whose vaccination history was ascertained before age 24 months (also at 35 months for ≥2 HepA doses).

<sup>†</sup> Data for the 2020 birth year are from survey years 2021 2022, and 2023; data for the 2021 birth year are considered preliminary and come from survey years 2022 and 2023 (data from survey year 2024 are not yet available).

<sup>§</sup> Children's health insurance status was reported by parent or guardian. "Other insurance" includes the Children's Health Insurance Program (CHIP), military insurance, coverage via the Indian Health Service, and any other type of health insurance not mentioned elsewhere.

<sup>¶</sup> Includes children who may have been vaccinated with diphtheria and tetanus toxoids vaccine or diphtheria and tetanus toxoids and pertussis vaccine.

\*\* Statistically significant ( $p < 0.05$ ) difference compared with the referent group.

<sup>††</sup> Includes children who may have been vaccinated with measles, mumps, rubella, and varicella combination vaccine.

<sup>§§</sup> Hib primary series: receipt of ≥2 or ≥3 doses, depending on product type received; full series: primary series and booster dose, which includes receipt of ≥3 or ≥4 doses, depending on product type received.

<sup>¶¶</sup> One dose HepB administered from birth through age 3 days.

<sup>\*\*\*</sup> Prior to 2020, first dose of HepA recommended at age 12-23 months, with second dose given 6-18 months after the first, depending upon the product type received. In 2020, recommendation revised to two doses between ages 12 and 23 months, at least 6 months apart. Since children in this analysis were vaccinated under both recommendations, coverage estimates for both <24 months and <35 months are provided.

<sup>†††</sup> Estimate not available because the unweighted sample size for the denominator was <30, or 95% CI half width/estimate >0.588, or 95% CI half-width was ≥10.

§§§ Includes  $\geq 2$  doses of Rotarix monovalent rotavirus vaccine (RV1), or  $\geq 3$  doses of RotaTeq pentavalent rotavirus vaccine (RV5). (If any dose in the series is either RotaTeq or unknown, default to 3-dose series.) The maximum age for the final rotavirus dose is 8 months, 0 days.

¶¶¶ Doses must be at least 24 days apart (4 weeks with a 4-day grace period); doses could have been received during two influenza seasons.

\*\*\*\* The combined 7-vaccine series (4:3:1:3\*:3:1:4) includes  $\geq 4$  doses of DTaP,  $\geq 3$  doses of poliovirus vaccine,  $\geq 1$  dose of measles-containing vaccine, the full series of Hib ( $\geq 3$  or  $\geq 4$  doses, depending on product type),  $\geq 3$  doses of HepB,  $\geq 1$  dose of VAR, and  $\geq 4$  doses of PCV.